PharmaVoice

JANUARY 2, 2025

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

126

126

MedCity News

JANUARY 2, 2025

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.

FDA 125

FDA Medicine Biopharma Pharma 125

pharmaphorum

JANUARY 2, 2025

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

104

104

MedCity News

JANUARY 2, 2025

Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries. The post AI Developers Need Real-World Data and Atropos Health Is Stepping Up to Help appeared first on MedCity News.

Networking 115

Networking Training Healthcare Healthcare 115

Advertiser: ZoomInfo

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

Sales

Pharmaceutical Technology

JANUARY 2, 2025

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Medical 102

Medical Marketing 102

pharmaphorum

JANUARY 2, 2025

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market

Marketing 96

Marketing 96

pharmaphorum

JANUARY 2, 2025

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price

95

95

MedCity News

JANUARY 2, 2025

About 79% of digital health leaders said their companies are pursuing new investment capital in the next year, according to a recent survey from Summit Health Advisors. The post Top Priorities and Challenges for Digital Health Leaders in 2025: 5 Key Insights appeared first on MedCity News.

93

93

pharmaphorum

JANUARY 2, 2025

Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug

94

94

PharmaTimes

JANUARY 2, 2025

MHRA urges caution over illegal medicines from beauty salons and social media

Medicine 88

Medicine Prescription Media 88

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

pharmaphorum

JANUARY 2, 2025

Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.

84

84

European Pharmaceutical Review

JANUARY 2, 2025

The National Institute for Health and Care Excellence (NICE) has recommended the first drug for NHS use to prevent cisplatin-induced hearing loss ( ototoxicity ) in children and young people between the ages of one month and 17 years old.Pedmarqsi (anhydrous sodium thiosulfate) is indicated for these children who have localised, non-metastatic, solid tumours.

Side effects 59

Side effects Medicine Government Pharmaceutical 59

PharmaTech

JANUARY 2, 2025

The guidance provides recommendations for those interested in participating in FDAs Advanced Manufacturing Technologies Designation Program.

Manufacturing 69

Manufacturing FDA 69

European Pharmaceutical Review

JANUARY 2, 2025

The RNA therapeutics industry stands poised for a transformative 2025, driven by breakthroughs in technology, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the unprecedented speed and success of mRNA-based COVID-19 vaccine development, the field has experienced a surge in investment and research to unlock the powerful potential of RNA for other therapeutic applications.

Manufacturing 59

Manufacturing Food and Drug Administration FDA Pharmaceutical 59

Advertiser: ZoomInfo

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

Sales Strategy

PharmaTech

JANUARY 2, 2025

The company is recalling one lot of PROGRAF 0.5mg (tacrolimus) and one lot of ASTAGRAF XL 0.5mg (tacrolimus extended-release) capsules because some bottles may contain empty capsules.

Pharma 64

Pharma 64

Pharmaceutical Technology

JANUARY 2, 2025

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.

Management 64

Management Physicians Patients 64

Pharmacy Times

JANUARY 2, 2025

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

Patients 58

Patients 58

Pharmaceutical Technology

JANUARY 2, 2025

Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable industry insights.

Leads 59

Leads Competition Pharmaceutical 59

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmaceutical Commerce

JANUARY 2, 2025

Lisa Arthurs, VP, trade, Two Labs, discusses a roundtable discussing women in trade as well as empowering future leaders.

Pharma 52

Pharma 52

Pharmaceutical Technology

JANUARY 2, 2025

The Phase III KOASTAL-1 study with Neumoras lead asset navacaprant failed to meet its primary and secondary endpoint.

Leads 59

Leads 59

PharmExec

JANUARY 2, 2025

Approval was based on results from the Phase III CheckMate-67T trial, which demonstrated non-inferior pharmacokinetics compared to intravenous Opvido.

FDA 52

FDA 52

Pharmaceutical Technology

JANUARY 2, 2025

MSD has received the UK MHRA approval for sotatercept, marketed as Winrevair, to treat PAH in the adult population.

Marketing 59

Marketing 59

Advertiser: ZoomInfo

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

Prospecting

PharmExec

JANUARY 2, 2025

Approval of Tevimbra was supported by the RATIONALE-305 Phase III trial, which demonstrated a significant overall survival benefit in patients with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

FDA 52

FDA Patients 52

Pharmaceutical Technology

JANUARY 2, 2025

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL)

Pharmaceutical 59

Pharmaceutical 59

Pharmaceutical Commerce

JANUARY 2, 2025

Is this level of involvement with HRSNs associated with higher burnout?

Physicians 52

Physicians 52

Pharmaceutical Technology

JANUARY 2, 2025

Severe asthma is traditionally classified into either high or low T-helper cell type 2 (T2) subtypes.

59

59

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

PharmaTech

JANUARY 2, 2025

Contract development and manufacturing organizations (CDMOs) are more critical than ever as the demand for advanced therapies continues to grow. Here are the CDMOs and service providers that are poised to make the biggest impact on the pharmaceutical industry.

Manufacturing 52

Manufacturing Pharmaceutical 52

Pharmaceutical Technology

JANUARY 2, 2025

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.

59

59

PharmExec

JANUARY 2, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmacy Times

JANUARY 2, 2025

The approval offers patients with solid tumors an alternative to intravenous PD-1 inhibitor administration.

Patients 49

Patients FDA 49

Advertiser: ZoomInfo

Sales and marketing leaders have reached a tipping point when it comes to using intent data — and they’re not looking back. More than half of all B2B marketers are already using intent data to increase sales, and Gartner predicts this figure will grow to 70 percent. The reason is clear: intent can provide you with massive amounts of data that reveal sales opportunities earlier than ever before.

Sales